A Phase I study of the pharmacokinetics, safety and tolerability of a novel tocopheryl phosphate mixture/oxymorphone transdermal patch system
Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans
Tags: analgesic, Numorphan®, Opana®, oxycodone metabolite, semi-synthetic opioid, µ-opioid receptor (MOR) agonist
BASi Method Number SAP.1710
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
